CN113825760B - 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 - Google Patents
一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 Download PDFInfo
- Publication number
- CN113825760B CN113825760B CN202080034445.5A CN202080034445A CN113825760B CN 113825760 B CN113825760 B CN 113825760B CN 202080034445 A CN202080034445 A CN 202080034445A CN 113825760 B CN113825760 B CN 113825760B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- degrees
- crystalline form
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910373071 | 2019-05-06 | ||
CN2019103730719 | 2019-05-06 | ||
CN201910380491 | 2019-05-08 | ||
CN201910380491X | 2019-05-08 | ||
PCT/CN2020/088748 WO2020224585A1 (zh) | 2019-05-06 | 2020-05-06 | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113825760A CN113825760A (zh) | 2021-12-21 |
CN113825760B true CN113825760B (zh) | 2022-08-19 |
Family
ID=73051250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080034445.5A Active CN113825760B (zh) | 2019-05-06 | 2020-05-06 | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220306622A1 (ja) |
EP (1) | EP3967698A4 (ja) |
JP (1) | JP7307817B2 (ja) |
CN (1) | CN113825760B (ja) |
WO (1) | WO2020224585A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101558067A (zh) * | 2006-08-23 | 2009-10-14 | 库多斯药物有限公司 | 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物 |
CN103030653A (zh) * | 2011-09-30 | 2013-04-10 | 上海恒瑞医药有限公司 | 杂芳基并嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
CN103588792A (zh) * | 2013-03-04 | 2014-02-19 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033894T2 (en) | 2006-08-23 | 2018-01-29 | Kudos Pharm Ltd | 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors |
WO2019085996A1 (zh) * | 2017-11-06 | 2019-05-09 | 南京明德新药研发股份有限公司 | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 |
-
2020
- 2020-05-06 EP EP20802767.2A patent/EP3967698A4/en active Pending
- 2020-05-06 US US17/594,980 patent/US20220306622A1/en active Pending
- 2020-05-06 WO PCT/CN2020/088748 patent/WO2020224585A1/zh unknown
- 2020-05-06 JP JP2021566043A patent/JP7307817B2/ja active Active
- 2020-05-06 CN CN202080034445.5A patent/CN113825760B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101558067A (zh) * | 2006-08-23 | 2009-10-14 | 库多斯药物有限公司 | 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物 |
CN103030653A (zh) * | 2011-09-30 | 2013-04-10 | 上海恒瑞医药有限公司 | 杂芳基并嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
CN103588792A (zh) * | 2013-03-04 | 2014-02-19 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
Non-Patent Citations (1)
Title |
---|
Optimization of Potent and Selective Dual mTORC1 and mTORC2 Inhibitors: The Discovery of AZD8055 and AZD2014;PIKE Kurt G. 等;《Bioorganic & Medicinal Chemistry Letters》;20130118;第23卷(第5期);第1212-1216页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020224585A1 (zh) | 2020-11-12 |
JP2022532099A (ja) | 2022-07-13 |
CN113825760A (zh) | 2021-12-21 |
EP3967698A1 (en) | 2022-03-16 |
JP7307817B2 (ja) | 2023-07-12 |
US20220306622A1 (en) | 2022-09-29 |
EP3967698A4 (en) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6605130B2 (ja) | 癌の治療のための血管拡張性失調症変異(atm)キナーゼの選択的モジュレーターとしての8−[6−[3−(アミノ)プロポキシ]−3−ピリジル]−1−イソプロピル−イミダゾ[4,5−c]キノリン−2−オン誘導体 | |
JP2018531226A6 (ja) | 癌の治療のための血管拡張性失調症変異(atm)キナーゼの選択的モジュレーターとしての8−[6−[3−(アミノ)プロポキシ]−3−ピリジル]−1−イソプロピル−イミダゾ[4,5−c]キノリン−2−オン誘導体 | |
KR20130122612A (ko) | 오에스아이 906의 다형체 | |
CN114728957B (zh) | 一种atr抑制剂的晶型及其应用 | |
CN112912380A (zh) | 一种mek抑制剂的晶型、无定形及其应用 | |
KR20190129923A (ko) | 듀테로화된 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료시 이들의 용도 | |
EP3896063B1 (en) | Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1) | |
CN113825760B (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
CN114315837B (zh) | 一种erk抑制剂的结晶形式及其制备方法 | |
WO2022048545A1 (zh) | 一种吡啶并嘧啶化合物的晶型 | |
CN115448874A (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
CN114144418B (zh) | 喹唑啉类化合物的晶型、盐型及其制备方法 | |
CN113646312B (zh) | 固体形式的brd4抑制剂化合物及其制备方法与应用 | |
CN116437915A (zh) | 一种吡咯并杂环类衍生物的晶型及其制备方法 | |
CN110437149B (zh) | 抗肿瘤活性的天然萘基异喹啉类化合物及其组合物、应用 | |
CN117355528B (zh) | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 | |
WO2014111031A1 (zh) | 三嗪化合物、其药用盐、异构体或水合物及其药物组合物 | |
CN115052877B (zh) | 一种氮杂吲哚衍生物的晶型及其应用 | |
CN113646313B (zh) | 一种a2a受体拮抗剂的盐型、晶型及其制备方法 | |
CN114380800B (zh) | 吡啶-嘧啶胺-苯并咪唑衍生物及其制备方法和用途 | |
CN113784968B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
US20240174681A1 (en) | Salt and crystalline forms of fgfr4 inhibitor and uses thereof | |
CN115232124A (zh) | 一种atx抑制剂的结晶形式及其制备方法 | |
CN115650975A (zh) | 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用 | |
CN114945565A (zh) | 一种吡咯烷基脲衍生物的晶型及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40062028 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |